Ideaya Biosciences Inc - Asset Resilience Ratio
Ideaya Biosciences Inc (IDYA) has an Asset Resilience Ratio of 49.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Ideaya Biosciences Inc's Asset Resilience Ratio has changed over time. Check IDYA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ideaya Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ideaya Biosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $513.68 Million | 49.85% |
| Total Liquid Assets | $513.68 Million | 49.85% |
Asset Resilience Insights
- Very High Liquidity: Ideaya Biosciences Inc maintains exceptional liquid asset reserves at 49.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ideaya Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Ideaya Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Ideaya Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.47% | $526.56 Million | $1.11 Billion | -5.19pp |
| 2024-12-31 | 52.66% | $591.94 Million | $1.12 Billion | -4.03pp |
| 2023-12-31 | 56.69% | $368.10 Million | $649.32 Million | -19.66pp |
| 2022-12-31 | 76.35% | $296.20 Million | $387.97 Million | +35.77pp |
| 2021-12-31 | 40.57% | $154.72 Million | $381.35 Million | -30.35pp |
| 2020-12-31 | 70.93% | $211.55 Million | $298.27 Million | +13.50pp |
| 2019-12-31 | 57.42% | $64.89 Million | $113.00 Million | -14.52pp |
| 2018-12-31 | 71.94% | $69.46 Million | $96.54 Million | +30.78pp |
| 2017-12-31 | 41.17% | $7.20 Million | $17.48 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more